ODTX

Odyssey Therapeutics Inc

24.53

Sep 18 • 11:44 AM ET +1.31 (5.66%)

Healthcare Biotechnology USA Small NASD

Peers: ARVN BBOT XNCR CGEM CTMX JANX KURA ALLO RVMD ROIV

| Held by: VTI VXF SCHA SCHB VTWO MSSM VTWG VTWV VTHR

Index	-
Market Cap	1.18B
Enterprise Value	893.35M
Income	-
Sales	-
Book/sh	8.80
Cash/sh	6.46
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	May 08, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.79
P/C	3.80
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.36
Current Ratio	11.36
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-4.87
EPS next Q	-1.08
EPS this Y	-14.06%
EPS next Y	17.31%
EPS next 5Y	2.20%
EPS past 3/5Y	-6.04% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-41.16%
Sales Q/Q	-100.00%
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	59.13%
Insider Trans	17.26%
Inst Own	30.18%
Inst Trans	70.57%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.14%
SMA50	12.80%
SMA200	24.23%
Trades

Shs Outstand	47.89M
Shs Float	19.64M
Short Float	11.25%
Short Ratio	8.54
Short Interest	2.21M
52W High	29.05 -15.54%
52W Low	15.10 62.48%
Volatility	9.74% 9.05%
ATR (14)	2.09
RSI (14)	52.94
Beta	-
Rel Volume	0.83
Avg Volume	258.59K
Volume	80,610

Perf Week	-0.39%
Perf Month	1.17%
Perf Quarter	28.66%
Perf Half Y	-
Perf YTD	22.67%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	35.75
Prev Close	23.22
Price	24.53
Change %	5.66%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-27-26	Initiated	H.C. Wainwright	Buy	$44
Jun-02-26	Initiated	Wedbush	Outperform	$30
Jun-02-26	Initiated	TD Cowen	Buy
Jun-02-26	Initiated	Oppenheimer	Outperform	$40
Jun-02-26	Initiated	JP Morgan	Overweight	$26
Jun-02-26	Initiated	Cantor Fitzgerald	Overweight

Sep-16-26 08:00AM	Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire) +5.14%
Aug-26-26 08:00AM	Odyssey Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-26 06:10AM	Evotec and Odyssey collaborate on AI-enabled R&D (Pharmaceutical Technology)
Aug-06-26 06:32AM	Odyssey Therapeutics: Q2 Earnings Snapshot (Associated Press)
Aug-04-26 07:00AM	Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +10.09%
12:56PM	Loading…
Jun-18-26 12:56PM	Kardigan rises in Nasdaq debut after upsized $400 million IPO (Reuters)
Jun-17-26 04:51PM	Odyssey Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:15PM	Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-26 08:31AM	Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip (GuruFocus.com) +6.27%

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

FounderDr. Gary D. Glick Ph.D.

Chief Financial OfficerMr. Jason Haas M.B.A.

Senior Vice President of Strategy & Business DevelopmentMr. Collin Todd

Ph.D.Prof. Eicke Latz M.D.

Scientific Co-FounderDr. Kim Lewis Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TPG GP A, LLC	Former 10% Owner	May 11 '26	Buy	18.00	1,388,889	25,000,002	3,690,146	May 13 05:10 PM
Dimension Capital II, L.P.	Director	May 08 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 12 05:37 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Buy	18.00	555,555	9,999,990	1,831,383	May 11 09:11 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '26	Sale	18.00	1,780	32,040	440,981	May 11 09:11 PM
LEIDEN JEFFREY M	Director	May 08 '26	Buy	20.00	5,000	100,000	270,198	May 11 08:35 PM
Haas Jason	Chief Financial Officer	May 08 '26	Buy	20.00	1,000	20,000	62,908	May 11 08:32 PM
Li Nan (LN)	Director	May 11 '26	Buy	18.00	1,111,111	19,999,998	3,333,516	May 11 08:30 PM
Chu Shelley	Director	May 11 '26	Buy	18.00	11,111	199,998	11,111	May 11 08:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ODTX

Odyssey Therapeutics Inc

Upgrade your Finviz experience